PRDX6通过对抗由HDAC抑制剂诱导的铁死来调节免疫检查点抑制剂反应
bioRxiv : the preprint server for biology
|February 6, 2026
概括
氧化素6 (PRDX6) 通过抑制铁亡,驱动对癌症疗法的耐药性,如HDAC抑制剂. 向PRDX6可以增强癌细胞死亡,并提高免疫治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 对胰岛素脱乙酶 (HDAC) 抑制剂和免疫检查点疗法的治疗耐药性在癌症治疗中构成了重大挑战.
- 虽然HDAC抑制剂可以诱导铁亡,但癌细胞经常通过抗氧化剂防御机制发展抵抗力.
研究的目的:
- 确定对HDAC抑制剂耐药性的关键调节剂,并探索新的治疗策略.
- 调查氧化素6 (PRDX6) 在抑制铁亡的作用及其对癌症免疫疗法的影响.
主要方法:
- 用全基因组的CRISPR激活查来确定耐药性因素.
- 生物化学测试和同源性瘤模型被用于研究PRDX6功能.
- 评估了PRDX6耗尽对脂质过氧化,铁和瘤微环境的影响.
主要成果:
- 鉴定出PRDX6是HDAC抑制剂拉加诱导的铁亡的关键抑制剂,通过脂酶A2活性和GPX4表达维持作用.
- 减少PRDX6显著增强了拉加索尔诱导的脂质过氧化和铁性压力.
- 打倒PRDX6促进了T细胞透和瘤微环境中的炎症性细胞因子释放.
结论:
- 在癌症中,PRDX6充当氧化还原守门人,将铁死耐药性与免疫逃避联系起来.
- 对PRDX6和HDAC通路的联合向增强了抗PD-L1免疫疗法的疗效,并延长了生存时间.
- 同时准PRDX6和HDAC通路是改善癌症免疫治疗反应的有希望的策略.
相关概念视频
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Humoral Immune Responses
84.0K
Overview
84.0K
Dipeptidyl Peptidase 4 Inhibitors
685
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
685
Antihypertensive Drugs: Direct Renin Inhibitors
1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615


